Quadrant Capital Group’s Ginkgo Bioworks DNA Stock Holding History

Quadrant Capital Group’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-448	Closed	-$3.72K	–	2740
2025 Q4	$3.72K	Hold	448	–	–	﹤0.01%	2428
2025 Q3	$6.53K	Buy	+448	New	+$5.36K	﹤0.01%	2268
2025 Q2	–	Sell	-12,499	Closed	-$71.2K	–	1691
2025 Q1	$71.2K	Buy	+12,499	New	+$127K	﹤0.01%	1613
2024 Q2	–	Sell	-5	Closed	-$216	–	2722
2024 Q1	$216	Sell	5 -100	-95%	-$5.18K	﹤0.01%	2686
2023 Q4	$7.08K	Buy	105 +37	+54%	+$2.27K	﹤0.01%	2186
2023 Q3	$4.9K	Hold	68	–	–	﹤0.01%	2181
2023 Q2	$5.03K	Buy	+68	New	+$4.03K	﹤0.01%	2201
2023 Q1	–	Sell	-25	Closed	-$1.66K	–	2740
2022 Q4	$1.66K	Buy	+25	New	+$2.3K	﹤0.01%	2461

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's DNA Position: Q1 2026 in Review

Quadrant Capital Group sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 448 shares — an estimated $3.72K sold.

Quadrant Capital Group first reported a position in DNA in Q4 2022 and held it in 8 quarters. The position peaked at $71.2K in Q1 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Quadrant Capital Group reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
Quadrant Capital Group sold 448 Ginkgo Bioworks shares in Q1 2026, an estimated $3.72K.
Quadrant Capital Group first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 8 quarters.
Quadrant Capital Group's Ginkgo Bioworks position peaked at $71.2K in Q1 2025.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.